Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders

Mayumi Naramura, Scott Nadeau, Bhopal Mohapatra, Gulzar Ahmad, Chandrani Mukhopadhyay, Martin Sattler, Srikumar M. Raja, Amarnath Natarajan, Vimla Band, Hamid Band

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Casitas B-lineage lymphoma (Cbl) family proteins are evolutionarily-conserved attenuators of protein tyrosine kinase (PTK) signaling. Biochemical analyses over the past two decades have firmly established that the negative regulatory functions of Cbl proteins are mediated through their ability to facilitate ubiquitination and thus promote degradation of PTKs. As aberrant activation of PTKs is frequently associated with oncogenesis, it has long been postulated that loss of normal Cbl functions may lead to unregulated activation of PTKs and cellular transformation. In the last few years, mutations in the CBL gene have been identified in a subset of human patients with myeloid malignancies. Here we discuss insights gained from the analyses of Cbl mutants both in human patients and in animal models and propose potential mechanisms of oncogenesis through this pathway.

Original languageEnglish (US)
Pages (from-to)245-250
Number of pages6
JournalOncotarget
Volume2
Issue number3
DOIs
StatePublished - Jan 1 2011

Fingerprint

Oncogene Protein v-cbl
Myeloproliferative Disorders
Mutant Proteins
Lymphoma
Carcinogenesis
Aptitude
Ubiquitination
Protein-Tyrosine Kinases
Animal Models
Mutation
Genes
Neoplasms

Keywords

  • Cbl
  • E3 ubiquitin ligase
  • Leukemia
  • Protein tyrosine kinase
  • Signal transduction

ASJC Scopus subject areas

  • Oncology

Cite this

Naramura, M., Nadeau, S., Mohapatra, B., Ahmad, G., Mukhopadhyay, C., Sattler, M., ... Band, H. (2011). Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders. Oncotarget, 2(3), 245-250. https://doi.org/10.18632/oncotarget.233

Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders. / Naramura, Mayumi; Nadeau, Scott; Mohapatra, Bhopal; Ahmad, Gulzar; Mukhopadhyay, Chandrani; Sattler, Martin; Raja, Srikumar M.; Natarajan, Amarnath; Band, Vimla; Band, Hamid.

In: Oncotarget, Vol. 2, No. 3, 01.01.2011, p. 245-250.

Research output: Contribution to journalArticle

Naramura, M, Nadeau, S, Mohapatra, B, Ahmad, G, Mukhopadhyay, C, Sattler, M, Raja, SM, Natarajan, A, Band, V & Band, H 2011, 'Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders', Oncotarget, vol. 2, no. 3, pp. 245-250. https://doi.org/10.18632/oncotarget.233
Naramura M, Nadeau S, Mohapatra B, Ahmad G, Mukhopadhyay C, Sattler M et al. Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders. Oncotarget. 2011 Jan 1;2(3):245-250. https://doi.org/10.18632/oncotarget.233
Naramura, Mayumi ; Nadeau, Scott ; Mohapatra, Bhopal ; Ahmad, Gulzar ; Mukhopadhyay, Chandrani ; Sattler, Martin ; Raja, Srikumar M. ; Natarajan, Amarnath ; Band, Vimla ; Band, Hamid. / Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders. In: Oncotarget. 2011 ; Vol. 2, No. 3. pp. 245-250.
@article{1cf7483aa6124ff89b37b67fa5fcba3b,
title = "Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders",
abstract = "Casitas B-lineage lymphoma (Cbl) family proteins are evolutionarily-conserved attenuators of protein tyrosine kinase (PTK) signaling. Biochemical analyses over the past two decades have firmly established that the negative regulatory functions of Cbl proteins are mediated through their ability to facilitate ubiquitination and thus promote degradation of PTKs. As aberrant activation of PTKs is frequently associated with oncogenesis, it has long been postulated that loss of normal Cbl functions may lead to unregulated activation of PTKs and cellular transformation. In the last few years, mutations in the CBL gene have been identified in a subset of human patients with myeloid malignancies. Here we discuss insights gained from the analyses of Cbl mutants both in human patients and in animal models and propose potential mechanisms of oncogenesis through this pathway.",
keywords = "Cbl, E3 ubiquitin ligase, Leukemia, Protein tyrosine kinase, Signal transduction",
author = "Mayumi Naramura and Scott Nadeau and Bhopal Mohapatra and Gulzar Ahmad and Chandrani Mukhopadhyay and Martin Sattler and Raja, {Srikumar M.} and Amarnath Natarajan and Vimla Band and Hamid Band",
year = "2011",
month = "1",
day = "1",
doi = "10.18632/oncotarget.233",
language = "English (US)",
volume = "2",
pages = "245--250",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "3",

}

TY - JOUR

T1 - Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders

AU - Naramura, Mayumi

AU - Nadeau, Scott

AU - Mohapatra, Bhopal

AU - Ahmad, Gulzar

AU - Mukhopadhyay, Chandrani

AU - Sattler, Martin

AU - Raja, Srikumar M.

AU - Natarajan, Amarnath

AU - Band, Vimla

AU - Band, Hamid

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Casitas B-lineage lymphoma (Cbl) family proteins are evolutionarily-conserved attenuators of protein tyrosine kinase (PTK) signaling. Biochemical analyses over the past two decades have firmly established that the negative regulatory functions of Cbl proteins are mediated through their ability to facilitate ubiquitination and thus promote degradation of PTKs. As aberrant activation of PTKs is frequently associated with oncogenesis, it has long been postulated that loss of normal Cbl functions may lead to unregulated activation of PTKs and cellular transformation. In the last few years, mutations in the CBL gene have been identified in a subset of human patients with myeloid malignancies. Here we discuss insights gained from the analyses of Cbl mutants both in human patients and in animal models and propose potential mechanisms of oncogenesis through this pathway.

AB - Casitas B-lineage lymphoma (Cbl) family proteins are evolutionarily-conserved attenuators of protein tyrosine kinase (PTK) signaling. Biochemical analyses over the past two decades have firmly established that the negative regulatory functions of Cbl proteins are mediated through their ability to facilitate ubiquitination and thus promote degradation of PTKs. As aberrant activation of PTKs is frequently associated with oncogenesis, it has long been postulated that loss of normal Cbl functions may lead to unregulated activation of PTKs and cellular transformation. In the last few years, mutations in the CBL gene have been identified in a subset of human patients with myeloid malignancies. Here we discuss insights gained from the analyses of Cbl mutants both in human patients and in animal models and propose potential mechanisms of oncogenesis through this pathway.

KW - Cbl

KW - E3 ubiquitin ligase

KW - Leukemia

KW - Protein tyrosine kinase

KW - Signal transduction

UR - http://www.scopus.com/inward/record.url?scp=80052048507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052048507&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.233

DO - 10.18632/oncotarget.233

M3 - Article

VL - 2

SP - 245

EP - 250

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 3

ER -